<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722447</url>
  </required_header>
  <id_info>
    <org_study_id>2016-000958-36</org_study_id>
    <nct_id>NCT02722447</nct_id>
  </id_info>
  <brief_title>Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis</brief_title>
  <acronym>RIDTS</acronym>
  <official_title>Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Ageno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of isolated distal deep vein thrombosis remains one of the most debated issues
      in the field of venous thromboembolism and only very few studies have directly addressed the
      issue of treatment in objectively confirmed isolated distal deep vein thrombosis. Aim of this
      study is to assess the long-term risk of recurrent venous thrombotic events in patients with
      a first acute symptomatic isolated distal deep vein thrombosis of the leg treated with a
      standard (12 weeks) or with a shorter (6 weeks) duration of therapy with rivaroxaban.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrent venous thromboembolism</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrent venous thromboembolism defined as new deep vein thrombosis, extension of distal deep vein thrombosis or pulmonary embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding events</measure>
    <time_frame>Until 2 days from the last intake of the study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically relevant non-major bleeding events</measure>
    <time_frame>Until 2 days from the last intake of the study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with residual vein occlusion</measure>
    <time_frame>3 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>Rivaroxaban 20 mg for 6 weeks</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Objective diagnosis of isolate distal deep vein thrombosis within 72 hours from the
             evaluation for inclusion in the study and if any type of parenteral treatment was
             administered at therapeutic doses for 3 days or less (maximum accepted doses of low
             molecular weight heparin: 6 doses; of fondaparinux: 3 doses).

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Any absolute contraindication to anticoagulant treatment

          -  Pregnancy or breast-feeding

          -  Presence of active cancer

          -  Concomitant presence of proximal deep vein thrombosis or pulmonary embolism

          -  Any concomitant indication for long-term anticoagulant treatment

          -  Creatinine clearance ≤30 ml/min, according to Cockcroft-Gault equation

          -  Cirrhosis Child-Pugh score B or C

          -  Liver disease associated with coagulopathy and high risk of bleeding

          -  Any other contraindication to rivaroxaban as per local SmPC

          -  Failure to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorenza Bertù, PhD</last_name>
    <phone>0039 0332 278831</phone>
    <email>lorenza.bertu@uninsubria.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale di Faenza</name>
      <address>
        <city>Faenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Bucherini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Padova</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Camporese, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Pieve di Soligo</name>
      <address>
        <city>Pieve di Soligo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Zanatta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Ghirarduzzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Cappelli, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Cappelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanna Colombo</last_name>
      <email>givacolo@hotmail.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Insubria</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Ageno, MD</last_name>
      <phone>+39-0332-278594</phone>
      <email>agewal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Dentali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Walter Ageno</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

